ArticleScientific reports2026
Device-driven cyclic compression of the superior vena cava as a preload reduction strategy to improve cardiac function in heart failure: a pilot feasibility study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We evaluated the physiological efficacy and safety of a novel device-based preload reduction strategy that applies external cyclic compression to the superior vena cava (SVC) in a preclinical heart failure model. Heart failure was induced in eleven pigs using ischemia-reperfusion injury, and a 3D-printed SVC compression device was tested under varying compression ratios (70%, 85%, and 100%) and protocols. Hemodynamic responses were monitored using right-heart catheterization and pressure-volume loop analysis. Among the tested conditions, cyclic compression at 85% with 20/5-minute compression-release cycles resulted in marked within-group improvements in key hemodynamic parameters. Cardiac output increased by 27.3% (3.83 to 4.88 L/min, Wilcoxon signed-rank test, p = 0.125) and stroke volume by 19.5% (38.6 to 46.1 mL, p = 0.125), while mean arterial and pulmonary pressures remained stable. Systemic vascular resistance decreased by 29.0% (from 1,200 to 852 dyn·s·cm
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.